ATOSSA THERAPEUTICS, INC. Fair Value Adjustment of Warrants
ATOSSA THERAPEUTICS, INC. (ATOS) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2022-02-28
- ATOSSA THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2017-12-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ATOSSA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2020 was $2.33M.
- ATOSSA THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2017 was $280.75K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $2.33M 10-K · filed 2022-02-28 | $2.33M 10-K · filed 2021-03-31 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $280.75K 10-K · filed 2019-03-28 | ||
| 2017-09-30 | $280.75K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |